Omega-3-carboxylic acids - Generic Drug Details

What are the generic drug sources for omega-3-carboxylic acids and what is the scope of freedom to operate?

Omega-3-carboxylic acids is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omega-3-carboxylic acids has eighty-five patent family members in forty-one countries.

There is one drug master file entry for omega-3-carboxylic acids.

Summary for omega-3-carboxylic acids

International Patents:	85
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	35
DailyMed Link:	omega-3-carboxylic acids at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for omega-3-carboxylic acids

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for omega-3-carboxylic acids

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Second Affiliated Hospital of Chongqing Medical University	NA
Mabaret Al-Asafara Hospitals	Phase 4
Assiut University	Phase 4

See all omega-3-carboxylic acids clinical trials

US Patents and Regulatory Information for omega-3-carboxylic acids

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No				Y
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No			Y
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No

Expired US Patents for omega-3-carboxylic acids

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014

International Patents for omega-3-carboxylic acids

Country	Patent Number	Title	Estimated Expiration
Mexico	358319	COMPOSICIONES ENRIQUECIDAS CON DPA DE LOS ÁCIDOS GRASOS POLINSATURADOS OMEGA-3 POLIINSATURADOS EN FORMA DE ÁCIDO LIBRE. (DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM.)
South Korea	20070011307	SOFT GELATIN CAPSULE COMPRISING OMEGA-3-POLYUNSATURATED FATTY ACID
Mexico	2014008309
Russian Federation	2018116572
Japan	2007522192
Costa Rica	20140350

Omega-3-carboxylic acids Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Omega-3 Carboxylic Acids?

The global market for omega-3 carboxylic acids is driven primarily by increasing awareness of cardiovascular health and demand for dietary supplements. The market's growth is influenced by factors including clinical evidence supporting efficacy, regulatory approvals, and healthcare provider preferences. Key drivers, restraints, and opportunities include:

Drivers

• Growing consumer awareness of omega-3s' role in reducing cardiovascular disease risk.
• Rising prevalence of hyperlipidemia and heart-related conditions.
• Shift from fish oil triglycerides to more bioavailable ethyl ester and carboxylic acid formulations.
• Expanding pharmaceutical pipeline focused on prescription-grade omega-3 products.

Restraints

• Stringent regulatory environments complicate approval processes.
• Variability in omega-3 sources and bioavailability concerns.
• Competition from dietary supplements and other lipid-lowering agents.

Opportunities

• Development of novel formulations with improved absorption.
• Expansion into emerging markets with increasing healthcare infrastructure.
• Integration with lipid-modifying therapies for synergistic effects.

Market Size and Forecast

The global omega-3 product market, estimated in 2022 at approximately USD 1.5 billion, is projected to grow at a CAGR of around 8% through 2027 [1]. Prescription omega-3 formulations, including fatty acid derivatives like omega-3-carboxylic acids, constitute a significant and rapidly expanding segment.

What Is the Financial Trajectory for Omega-3 Carboxylic Acids?

The financial outlook for omega-3 carboxylic acids depends on several factors: regulatory approval status, market penetration, pricing strategy, and competitive landscape.

Revenue Projections

• The top-selling prescription omega-3 drugs, such as Vascepa (icosapent ethyl), generated over USD 1 billion in annual revenues before patent expiration.
• Omega-3 carboxylic acids based on prescriptions are valued at an estimated USD 150-250 million globally as of 2022, with potential to reach USD 500 million or more by 2025 assuming increased approvals and market share.

Pricing and Reimbursement

• Prices vary; branded formulations can command USD 100-300 per month.
• Reimbursement policies differ by country; in the U.S., Medicare and private insurers largely reimburse for prescribed lipid therapies when indicated.

Competitive Landscape

Major players include AstraZeneca, Amarin, and generic manufacturers. Patent protections, such as exclusivity periods for key formulations, influence revenue potential.

Investment Considerations

• Companies with pipeline compounds progressing through clinical trials likely will see accelerated revenue growth post-approval.
• Patent expirations in the next 3-5 years could open market share to generics, pressuring pricing and margins.

How Do Regulatory and Scientific Factors Impact Market and Financial Outcomes?

Regulatory approval processes significantly influence market entry and revenue projections. The U.S. Food and Drug Administration (FDA)’s approval of Vascepa and subsequent labeling for cardiovascular risk reduction set robust precedents. Similar pathways are likely for new omega-3 carboxylic acid drugs deploying rigorous clinical data.

Research indicating superior bioavailability and tolerability over fish oil triglycerides bolsters commercialization prospects. Conversely, adverse regulatory decisions or failures in clinical trials can negatively impact financial trajectories.

Key Market Players and Their Strategic Moves

• AstraZeneca markets Vascepa, with expanded labeling indicating cardiovascular benefits.
• Amarin Corporation remains focused on marketing and expanding indications for icosapent ethyl.
• Generic manufacturers are poised to enter post-patent expiration, increasing competitive pressure.

Summary of Opportunities and Risks

Aspect	Details
Opportunities	Patent extensions, approval in emerging markets, combined therapy protocols
Risks	Regulatory rejection, payment policy barriers, manufacturing quality concerns

Key Takeaways

• The global omega-3 carboxylic acids market is forecasted to grow steadily at around 8% CAGR through 2027 due to increasing cardiovascular health focus.
• Pharmaceutical sales are influenced by clinical efficacy data, regulatory milestones, and market penetration.
• Revenues for prescription omega-3 drugs, including omega-3 carboxylic acids, are projected to reach USD 500 million+ by 2025, with growth potential post-patent expiration.
• Prices range from USD 100 to 300 per month, with reimbursement policies affecting market access.
• Competitive forces include brand dominance, patent status, and the entry of generics.

---

FAQs

1. What distinguishes omega-3 carboxylic acids from other omega-3 formulations?
They have improved bioavailability and tolerability due to their chemical structure, offering potentially increased efficacy over fish oil triglycerides.

2. How does regulatory approval impact financial outcomes?
Approval confirms clinical efficacy and safety, enabling commercialization and revenue generation; delays or denials stall growth.

3. What are the primary markets for these drugs?
The U.S., Europe, and Japan are the leading markets, with emerging markets showing increased adoption potential.

4. How significant is patent protection duration?
Patents typically last 20 years from filing, but exclusivity periods post-approval can range from 5 to 12 years, influencing market share and revenue.

5. What potential competitive threats exist?
Generic entries following patent expiry and shifts in reimbursement policies can erode market share.

---

References

[1] MarketWatch, "Omega-3 Products Market Size, Share & Trends Analysis," 2022.